The World Clinical Biomarkers and CDx Summit is back! Gathering 600+key stakeholders across biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market.

See the 3-tracked, 2 day agenda and 65+ expert speaker faculty here.

Develop, Validate & Commercialize Clinically Effective Targeted Therapeutics

The diagnostic field is booming with global interest as companies race to be the first to develop diagnostics and vaccines for the novel coronavirus. More than ever before we are seeing diagnostic, pharmaceutical and academic expertise coming together to deliver in record-breaking speed. As attention starts to shift back to existing pipeline candidates, what lessons can we learn to deliver personalized therapies in a more time effective manner?

Uniting biomarker, translational, clinical, diagnostic and commercial thought leaders, the
Digital Clinical Biomarkers & World CDx meeting will address key questions raised following the rapid COVID-19 response and delivers exciting case studies from pioneering teams in personalized therapeutics. Helping you expedite end-to-end drug development; this is not a conversation to miss.

With three days dedicated to help you overcome your most pressing challenges, ensure you are here for conversations with pharma on the COVID response, the rise of T-cell based therapeutics in personalized medicine and exciting case studies spanning early studies to delivering commercial strategies

Key Speakers

Tooba Cheema

Director, Translational Medicine & Biomarkers


Jennifer Hamilton

Executive Director & Head, Precision Medicine


Sid Mathur

Regulatory Affairs Director, Companion Diagnostics

Merck & Co.

Julie Ramage

Director, Precision Medicine Quality Initiatives & Partnerships


Lourdes Barrera

Senior Director, Precision Medicine, Global Precision Medicine Strategy, Oncology Business Unit


Jeffrey Emch

Vice President, Global Companion Diagnostics Strategy, Oncology


Beth Trehu

Chief Medical Officer

Jounce Therapeutics

Roman Yelensky

Chief Technology Officer

Gritstone Oncology